Wells Fargo raised the firm’s price target on Kestra Medical (KMTS) to $28 from $27 and keeps an Overweight rating on the shares. The firm notes the company reported Q2 sales in-line with its pre-announcement and raised FY26 sales guidance above the Q2 beat. Management highlighted an acceleration in WCD market growth, share capture, and improvement in in-network mix and RCM as driving its outlook.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical price target raised to $30 from $27 at Piper Sandler
- Kestra Medical Technologies: Strong Financial Performance and Market Leadership Drive Buy Rating
- Closing Bell Movers: Broadcom down 5%, Lululemon gains 10%
- Kestra Medical reports Q2 EPS (64c), consensus (57c)
- Kestra Medical raises FY26 revenue view to $91M from $88M, consensus $88.02M